From: Novel phenotypes of coronavirus disease: a temperature-based trajectory model
Demographics | Survivors (n = 1357) | Non-survivors (n = 223) | All patients (n = 1580) | p |
---|---|---|---|---|
Age (years) | 56.2 ± 13.9 | 67.1 ± 12.4 | 57.7 ± 14.2 | < 0.001 |
Male [n (%)] | 703 (51.8) | 136 (60.9) | 839 (53.1) | 0.011 |
Comorbidities | ||||
Hypertension [n (%)] | 322 (23.7) | 75 (33.6) | 397 (25.1) | 0.002 |
Diabetes mellitus [n (%)] | 141 (10.3) | 43 (19.2) | 184 (11.6) | < 0.001 |
Chronic heart diseases [n (%)] | 77 (5.6) | 27 (12.1) | 104 (6.5) | < 0.001 |
COPD [n (%)] | 15 (1.1) | 11 (4.9) | 26 (1.6) | < 0.001 |
Chronic renal diseases [n (%)] | 27 (2.0) | 7 (3.1) | 34 (2.1) | 0.273 |
Malignant tumor [n (%)] | 31 (2.3) | 14 (6.2) | 45 (2.8) | < 0.001 |
Laboratory and disease severity indexes | ||||
Initial white blood cell count (10^9/L) | 6.6 ± 3.2 | 10.2 ± 5.2 | 7.1 ± 3.7 | < 0.001 |
Maximum white blood cell count (10^9/L) | 7.8 ± 3.6 | 16.5 ± 8.8 | 9.0 ± 5.6 | < 0.001 |
Initial neutrophil count (10^9/L) | 4.6 ± 2.6 | 8.3 ± 4.8 | 5.1 ± 3.3 | < 0.001 |
Maximum neutrophil count (10^9/L) | 5.7 ± 3.3 | 14.1 ± 8.0 | 6.9 ± 5.2 | < 0.001 |
Initial lymphocyte cell count (10^9/L) | 1.2 ± 0.6 | 0.8 ± 0.6 | 1.1 ± 0.6 | < 0.001 |
Minimum lymphocyte cell count (10^9/L) | 1.0 ± 0.6 | 0.5 ± 0.4 | 0.9 ± 0.6 | < 0.001 |
Initial hemoglobin level (g/dl) | 122.6 ± 16.7 | 119.9 ± 19.1 | 122.2 ± 17.1 | 0.025 |
Initial platelet count (10 /L) | 224 ± 89 | 166 ± 73 | 216 ± 89 | < 0.001 |
Initial albumin level (g/L) | 33.9 ± 4.3 | 30.4 ± 4.2 | 33.4 ± 4.5 | < 0.001 |
Initial serum creatinine (mmol/l) | 72.1 ± 33.1 | 96.3 ± 78.6 | 75.5 ± 43.3 | < 0.001 |
PaO2/FiO2 | 283 ± 128 | 170 ± 146 | 266 ± 137 | < 0.001 |
Initial CRP level (mmol/L) | 29 ± 35 (n = 30) | 84 ± 49 (n = 43) | 36 ± 41 (n = 343) | < 0.001 |
Maximum CRP level (mmol/L) | 38 ± 41 (n = 30) | 118 ± 46 (n = 43) | 48 ± 49 (n = 343) | < 0.001 |
SOFA score on admission [median (IQR)] | 1 (0–2) | 3 (1–4) | 1 (0–2) | < 0.001 |
Maximum SOFA score [median (IQR)] | 1 (0–2) | 6 (4–9) | 1 (0–2) | < 0.001 |
Study center | 0.011 | |||
Union Jiangbei Hospital | 160 (11.7) | 35 (15.6) | 195 (12.3) | |
Wuhan No.9 Hospital | 138 (10.1) | 25 (11.2) | 163 (10.3) | |
Wuhan No.4 Hospital | 42 (3.1) | 11 (4.9) | 53 (3.3) | |
Wuhan Jinyintan Hospital | 1003 (73.9) | 145 (65.0) | 1148 (72.6) | |
Huangshi central Hospital | 14 (1.0) | 7 (3.1) | 21 (1.3) | |
Immunotherapy | ||||
Corticosteroid therapy [n (%)] | 300 (22.1) | 117 (52.4) | 417 (26.3) | < 0.001 |
Interferon therapy [n (%)] | 198 (14.5) | 34 (15.2) | 232 (13.8) | 0.798 |
Gamma-globulin therapy [n (%)] | 270 (19.8) | 88 (39.4) | 358 (21.3) | < 0.001 |
Clinical outcomes | ||||
ARDS [n (%)] | 180 (13.2) | 197 (88.3) | 377 (23.8) | < 0.001 |
Mechanical ventilation [n (%)] | 26 (1.9) | 78 (34.9) | 104 (6.5) | < 0.001 |
Duration of mechanical ventilation (days) | 10.3 ± 3.7 | 5.6 ± 4.6 | 6.7 ± 4.8 | < 0.001 |
Hospital length of stay (days) | 13.5 ± 7.1 | 10.5 ± 7.0 | 13.0 ± 7.1 | < 0.001 |
ICU admission [n (%)] | 164 (12.1) | 109 (48.8) | 273 (17.2) | < 0.001 |
ICU length of stay (days) | 10.4 ± 10.3 | 8.3 ± 7.3 | 9.6 ± 9.3 | 0.064 |